Alexander Mm Eggermont

9PUBLICATIONS
86CO-AUTHORS
Cancer geneticsPredictive and prognostic markersCancer diagnosisCancer therapy (excl. chemotherapy and radiation therapy)Gene and molecular therapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Apr 04, 2024
The Virtual Child.

Richard J Gilbertson, Sam Behjati, Anna-Lisa Böttcher

|Mar 07, 2024
Pembrolizumab Versus Placebo as Adjuvant Therapy in Resected Stage IIB or IIC Melanoma: Final Analysis of Distant Metastasis-Free Survival in the Phase III KEYNOTE-716 Study.

Jason J Luke, Paolo A Ascierto, Muhammad A Khattak

|Dec 15, 2023
Shifting landscape in skin cancer incidence: the rising tide of cutaneous squamous cell carcinoma and potential implications for prevention.

Celeste J Eggermont, Alexander M M Eggermont

|Sep 04, 2023
COLUMBUS-AD: phase III study of adjuvant encorafenib + binimetinib in resected stage IIB/IIC BRAF V600-mutated melanoma.

Alexander Cj van Akkooi, Axel Hauschild, Georgina V Long

|Jun 16, 2022
Prognosis of Patients With Primary Melanoma Stage I and II According to American Joint Committee on Cancer Version 8 Validated in Two Independent Cohorts: Implications for Adjuvant Treatment.

Claus Garbe, Ulrike Keim, Teresa Amaral

|Apr 26, 2022
Optimal systemic therapy for high-risk resectable melanoma.

Alexander M M Eggermont, Omid Hamid, Georgia V Long

Pageof 2

Frequent Collaborators

4 joint publications

Georgina V Long

3 joint publications

Jason J Luke

3 joint publications

Paolo A Ascierto

3 joint publications

Dirk Schadendorf